Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

EGF promotes mammalian cell growth by suppressing cellular senescence

(2014) Peter B Alexander et al.   CELL RESEARCH

Drug resistance to targeted therapies: Déjà vu all over again

(2014) Floris H. Groenendijk et al.   Molecular Oncology

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies

(2014) Chong Sun et al.   TRENDS IN BIOCHEMICAL SCIENCES

RON confers lapatinib resistance in HER2-positive breast cancer cells

(2013) Quanren Wang et al.   CANCER LETTERS

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

(2013) Justin F. Gainor et al.   JOURNAL OF CLINICAL ONCOLOGY

The quest to overcome resistance to EGFR-targeted therapies in cancer

(2013) Curtis R Chong et al.   NATURE MEDICINE

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer

(2013) M. J. Niederst et al.   Science Signaling

Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks

(2013) J. P. Wagner et al.   Science Signaling

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M

(2012) Ho-June Lee et al.   Cancer Discovery

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

(2010) Shivanni Kummar et al.   NATURE REVIEWS DRUG DISCOVERY

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

(2010) D Ercan et al.   ONCOGENE

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

(2009) A. C. Faber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogene Addiction

(2008) I. B. Weinstein et al.   CANCER RESEARCH

Kinase requirements in human cells: I. Comparing kinase requirements across various cell types

(2008) D. A. Grueneberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA